Phase 3 Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were receiving ongoing ocrelizumab treatment in one of a specific list of related earlier studies (called "parent studies") at the time of transferring into this trial, and for whom ocrelizumab treatment is not available locally.
- People whose first dose in this extension trial will be given no earlier than 5 months after their last treatment dose in the parent study.
- People who can produce a negative pregnancy test (urine) within 24 hours before their first dose in this trial, if they are of childbearing potential.
Who may not be able to join:
- People for whom ocrelizumab is commercially available and reasonably accessible in their country for their specific condition.
- People for whom ocrelizumab is available through a Post Trial Access Program (a scheme that provides continued access to a study treatment after a trial ends) in their country.
- People who permanently stopped the study treatment for any reason during the parent study, or in the period between their last parent study dose and their first dose in this extension trial.
- People who have any condition that, in the investigator's opinion, could interfere with assessing their safety or could put them at high risk of treatment-related complications.
- People who are currently participating in another therapeutic clinical trial (other than the parent study).
- People who have a weakened immune system.
- People who have a known active cancer, or who are being actively monitored for cancer returning.
- People who have other known neurological conditions (conditions affecting the brain, spinal cord, or nerves).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Phone: 888-662-6728 (U.S. Only)
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change From Baseline to End of Study in the Physical Functioning Score of the Patient-Reported Outcome Measure Information System/Quality of Life in Neurological Disorders - Physical Function Measure for Multiple Sclerosis 15a (PROMISnq PFMS-15a); Number of Eligible Participants who Have Received Access to Ocrelizumab in the Study
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.